Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Nov 2026: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Carson Cumberbatch✕ CARS · #13,416 in the world | Indivior PLC✕ INDV · #3,650 in the world |
|---|---|---|
| Profile | ||
| Country | 🇱🇰 Sri Lanka | 🇬🇧 UK |
| Sector | Healthcare | Healthcare |
| Industry | — | Pharmaceutical |
| Founded | — | 1994 |
| Size | ||
| Market cap | ||
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Carson Cumberbatch | Indivior PLC |
|---|---|---|
| 2025 | — | $1.2 BSEC |
| 2024 | — | $1.2 BSEC |
| 2023 | — | $1.1 BSEC |
| 2022 | — | $901 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $410 M |
| $4.9 B |
| Revenue | — | $1.2 B |
|---|
| Net income | — | $210 M |
|---|
| Valuation | ||
|---|---|---|
| P/E ratio | — | 10.8× |
| Price to sales | — | 3.5× |
| Free cash flow yield | — | -1.9% |
| Profitability | ||
|---|---|---|
| Gross margin | — | 80.2% |
| Operating margin | — | 21.1% |
| Net margin | — | 16.9% |
| Growth | ||
|---|---|---|
| Revenue growth | — | 4.3% |
| Revenue growth, 3 years a year | — | 11.2% |
| Financial strength | ||
|---|---|---|
| Net debt to EBITDA | — | 0.3× |
| Interest cover | — | 6.9× |
| Cash | ||
|---|---|---|
| Free cash flow margin | — | -7.5% |
| Shareholder returns | ||
|---|---|---|
| Shareholder yield | — | 0.2% |
| Strength scores | ||
|---|---|---|
| Piotroski F-score | — | 4 of 9 |
| Altman Z-score zone | — | safe |
|---|
| Data as of | Market cap Nov 2026 | Market cap Aug 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.